In addition, although ICAM‐1+/Ki67+ cancer cells survived ICAM‐1 treatment, they became exceedingly rare following ICAM‐1–Dxd treatment in organoid cultures (Figure 3G), further validating the promising therapeutic potential of ICAM‐1–Dxd in the management of TNBC. This evidence concerns the gene ICAM1 and cancer.